SNM gains support for research and clinical trials

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

The Society of Nuclear Medicine (SNM) announced it has received nearly $3.3 million in corporate pledges for its “Bench to Bedside” fundraising effort. The organization plans to use the funds to support efforts by its Molecular Imaging Center of Excellence, such as translational research, clinical research and clinical trials, outreach activities, advocacy efforts, and to train the current imaging workforce and educate future practitioners on the applications of molecular imaging.

“We are at an important phase, moving from the initial planning stage into an advocacy, educational and research phase of our five-year action plan to bring molecular imaging research from bench to bedside,” said SNM President Martin P. Sandler. “As we move forward, we always keep the focus on how our initiatives relate to the all-important goal of transforming patient care,” he added.

Corporate sponsorship has come from GE Healthcare, Bristol-Myers Squibb Medical Imaging, Siemens Medical Solutions USA, IBA Molecular, Philips, MDS Nordion, Cardinal Health and FluoroPharma to bring molecular imaging advances from preliminary research into clinical implementation.

SNM said it also plans to develop a new informational website for launch this summer and increased advocacy efforts on Capitol Hill.

The new Molecular Imaging Center of Excellence site will be a repository of information for researchers, physicians, patients or anyone interested in molecular imaging. Meanwhile, SNM members will meet with legislators and decision makers in Washington D.C., during the society’s annual meeting this June, to discuss issues relating to molecular imaging.